See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Vatican
Olaf Scholz
Volodymyr Zelenskyy
Ukraine War
Donald Trump
Israel-Hamas Conflict
German Politics
Elon Musk
Basketball
Tennis
Hamas
Published • loading... • Updated

Guerbet receives FDA Breakthrough Device designation for Lipiojoint liquid embolic - Interventional News

Summary by Interventional News
Guerbet has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Lipiojoint, the company’s transient liquid embolic agent designed to alleviate pain and the related burden of reduced mobility in patients with knee osteoarthritis (OA). This recognition highlights the potential of Lipiojoint as a minimally invasive and targeted approach for knee OA patients who have not found relief through non-su…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
Interventional NewsInterventional News

Guerbet receives FDA Breakthrough Device designation for Lipiojoint liquid embolic - Interventional News

Guerbet has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Lipiojoint, the company’s transient liquid embolic agent designed to alleviate pain and the related burden of reduced mobility in patients with knee osteoarthritis (OA). This recognition highlights the potential of Lipiojoint as a minimally invasive and targeted approach for knee OA patients who have not found relief through non-su…

Read Full Article
Endovascular TodayEndovascular Today

Guerbet’s Lipiojoint Liquid Embolic Granted FDA Breakthrough Device Status - Endovascular Today

February 10, 2025—Guerbet announced that its Lipiojoint transient liquid embolic agent received Breakthrough Device status from the United States FDA. According to the company, the Lipiojoint embolic agent is being developed for genicular artery embolization. Lipiojoint is designed to alleviate pain and the related burden of reduced mobility in patients with knee osteoarthritis. Marc Sapoval, MD, et al recently published clinical data from the L…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Endovascular Today broke the news in on Monday, February 10, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

FDA

FDA

Maryland

Maryland

News
For You
Search
BlindspotLocal